Time-varying caloric vestibular stimulation for the treatment of neurodegenerative disease.

Loading...
Thumbnail Image

Date

2022-01

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

23
views
24
downloads

Citation Stats

Attention Stats

Abstract

Time-varying caloric vestibular stimulation (tvCVS) is a new form of non-invasive neuromodulation similar to, but different from, diagnostic caloric vestibular stimulation (CVS). Using a non-invasive, solid-state delivery device, tvCVS has been successfully used in a human clinical trial with Parkinson's disease (PD) subjects. Additionally, the effects of tvCVS on brain activation have been studied in healthy human subjects using transcranial Doppler sonography (TCD) and functional magnetic resonance imaging (BOLD fMRI). A novel finding in the TCD and fMRI studies was the induction of cerebral blood flow velocity (CBFv) oscillations. How such oscillations might lead to the observed clinical effects seen in PD subjects will be discussed. Enabling studies of tvCVS with rodents is an attractive goal in support of explorations of the mechanism of action. Male Wistar rats were used in a proof-of-concept study described herein. Rats were anesthetized (isoflurane) and ventilated for the duration of the tvCVS runs. Time-varying thermal stimuli were administered using a digital temperature controller to modulate Peltier-type heater/cooler devices. Blunt ear bars conveyed the thermal stimulus to the external ear canals of the rats. Different thermal waveform combinations were evaluated for evidence of successful induction of the CVS effect. It was found that bilateral triangular thermal waveforms could induce oscillations in CBFv both during and after the application of tvCVS. These oscillations were similar to, but different from those observed in awake human subjects. The establishment of a viable animal model for the study of tvCVS will augment ongoing clinical investigations of this new form of neuromodulation in patients with neurodegenerative disease.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.3389/fnagi.2022.1049637

Publication Info

Black, Robert D, and Eduardo Chaparro (2022). Time-varying caloric vestibular stimulation for the treatment of neurodegenerative disease. Frontiers in aging neuroscience, 14. p. 1049637. 10.3389/fnagi.2022.1049637 Retrieved from https://hdl.handle.net/10161/26347.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Chaparro

Eduardo Chaparro

Research Scholar

Dr. Chaparro earned his Medical Doctorate from Javeriana University in Bogotá, Colombia, and his Ph.D. in Medical Sciences with a specialization in Physiology, Pharmacology, and Neuroscience from the University of South Florida (USF) in Tampa, Florida. During his graduate studies at USF’s Anesthesiology Department, he investigated the effects of anesthetics and anti-apoptotic compounds on brain ischemia.

Following the completion of his Ph.D., Dr. Chaparro pursued post-doctoral training at Duke University’s Multidisciplinary Neuroprotection Laboratory. Here, he focused on testing drugs and devices in various animal models of neurological conditions. His work received special recognition for the successful testing of the first hepatocyte growth factor mimetic in an animal model of transient cerebral ischemia. Additionally, he successfully tested an FDA-approved vestibular stimulator for human use.

Dr. Chaparro then joined the Cerebrovascular and Skull Base Division at Duke University’s Department of Neurosurgery. His research has been dedicated to developing treatments for neurovascular conditions such as stroke, moyamoya disease, aneurysms, intracerebral hemorrhages, intravascular stent thrombogenicity, traumatic brain injury, and epilepsy. He currently serves as the Director of the Neurovascular Laboratory.

An entrepreneur at heart, Dr. Chaparro’s interest in hypothermia as a treatment for neuronal inflammation led him to patent a brain-cooling device, which has been successfully tested in non-human primates. He founded Neurocool, a startup aimed at further developing this prototype. As Medical Director, he is working towards FDA approval and the development of a human-compatible device to aid patients with central nervous system inflammatory conditions.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.